TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plasma concentration of rivaroxaban characterized by AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of rivaroxaban characterized by AUC/D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of rivaroxaban characterized by Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of rivaroxaban characterized by Cmax/D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive pneumococcal disease incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Intracranial pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety measured by Spielberger State Anxiety Inventory (STAI-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety measured by Dental Fear Survey (DFS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety measured by Modified Dental Anxiety Scale (MDAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety measured by Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: disease activity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion time of a pointing task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error rate of the pointing task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the pointing task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional Network Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in plasma MDA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in MDA concentration on LDL fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-operative Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Late Life Function and Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma Trough Levels of Guanfacine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of days with documented episodes of paroxysmal atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Onset of Perceptible Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in IOP at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Prevalence of alcoholic hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: CDR Sum of boxes (CDR-SB) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Response to Treatment (ACR20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hypoventilation / Respiratory Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Treatment-related Adverse Events Per Study Arm
Endpoint domain: Adverse events/effects
Primary endpoint: T Cell Response in Peripheral Blood Over Duration of Study Participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants developing active tuberculosis
Endpoint domain: Adverse events/effects
Primary endpoint: feasibility and safety of NGRhTNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with treatment related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in fractures position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IBS prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum concentration of plasma relacorilant (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of plasma relacorilant (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance of leucocytes to inflammatory activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sexual Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frailty status defined according to Geriatric assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty status defined according to biomarkers of frailty: Telomere Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty status defined according to biomarkers of frailty: miRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty status defined according to biomarkers of frailty: CDKN2A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Jaw Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Symptom of GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of treatments to achieve 50% change in MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Take Notice behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of disease causing genogroups of N. meningitidis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Discriminative stimulus effects of smoked marijuana
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reinforcing effects of smoked marijuana
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in identification of correct/incorrect child car safety seat and booster seat situations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in identification of bicycle helmet placement situations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen uptake (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25 OH vitamin D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological/functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: OSATURB total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Vital Sign: Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pressure of lower esophageal sphincter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pressure of intragastric
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of glucose absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional impairment of peripheral atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Placenta Tissues Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in number of courses of antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in number of courses of corticosteroid therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in number of COPD medication therapy changes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Experienced Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Assessment of HER2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Semiquantitative Assessment of Breast and other Metastatic Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of 99mTc-NM-02 through Adverse Event Monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of vaccine-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of clinical safety laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of new-onset chronic medical conditions
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of subjects with detectable S. mansoni eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Rate of Change in Brain Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Nutritional Interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: level of serum ammonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Severe (Grade 3) Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Tetanus vaccination coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 25-hydroxyvitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PVD status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of RD
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Subjective Contact Lens-related Dryness Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poorer perinatal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Abemaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predose Concentration (Cmin) of Abemaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Abemaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve (AUC) of Abemaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recommended phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of treatment-emergent AEs and SAEs as assessed by vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent AEs and SAEs as assessed by ECGs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent AEs and SAEs as assessed by clinical laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent AEs and SAEs as assessed by psychometric tests
Endpoint domain: Adverse events/effects
Primary endpoint: EVENDOL pain score at four weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Housing placement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in saccadic peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearance of the scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in urine glucose excretion per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in urine glucose excretion per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in mean 24-hour plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients identified with high risk for PNH clone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of end of life care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC(0 to infinity) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescribing rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of first acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: flow-mediated dilation of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Natural history and outcomes of severe asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Changes in Color, Texture, and Size of Cherry Angiomata
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intent to use alcohol or tobacco products
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood Levels of Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTX absolute difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area-under-the-serum insulin concentration versus time curve (AUC0-240min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentages of Subjects With hSBA ≥ Lower Limit Quantitation (LLQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Subjects With hSBA ≥ 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean hSBA Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BrainHealth Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Magnetic Resonance Imaging (fMRI) Measure of Neural Correlations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identification of genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum RBP4 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric Mean Fold Rise in Serum Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Count of Participants With 4-fold Rise in ELISA Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Analogue Scale Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical relevant deviations from Laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from vascular or endovascular arterial intervention below the knee
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from major amputation of the study leg
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline scores of the Center for Epidemiologic Studies Depression scale (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline scores of the Revised version of the Peer Experiences Questionnaire (RPEQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline levels of Cortisol, DHEA and testosterone (in saliva)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: UPDRS motor evaluation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of the digital application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined cardiac related re-hospitalizations and all cause mortality (14-day and 30-day)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of HSV-2
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline Brachial Artery Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Microparticle Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Completion of Cardiac Rehabilitation Program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change of biomarkers of survival
Endpoint domain: Mortality/survival
Primary endpoint: Long-term clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic performance of CTC for colorectal polyp detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in histone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum β-hydroxybutyrate (BHB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatic Steatosis by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Strain Echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite of ischemic stroke/systemic embolism/transient ischemic attack (TIA)
Endpoint domain: Mortality/survival
Primary endpoint: Change in re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Comparison of scarring between donor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Comparison of hypopigmentation between donor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity of enhanced cardiac sarcoidosis screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Social Responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Work Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Social Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Empathic Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Job Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Identification of a new ALS biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngeal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ability to perform sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Intraocular Pressure (IOP) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of complete and partial remissions (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Any Grade Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 or Higher Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiopulmonary Exercise Test (CPET) VO2 Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean daily step counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Unanticipated Serious Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline OCT at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from multifocal ERG at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of additional identified polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of Esophageal Peristaltic Reflexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nicotine, alcohol and drug abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste appreciation and detection changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes